Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Molinaro

Showing results (291-300 of 336) with videos related to

Pageof 34
Sort By:
Neuro-Oncology|January 2, 2025
Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomideGeno Guerra, George Wendt, Lucie McCoy, et al.
Neuro-Oncology Advances|July 25, 2025
Dissecting the biology of gliomagenesis: Evaluating the interaction between <i>IDH</i> tumor mutation and germline variantsMatthew L Kosel, Paul A Decker, Thomas M Kollmeyer, et al.
Neuro-Oncology Advances|December 23, 2020
Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adultsJessica D Schulte, Robin A Buerki, Sarah Lapointe, et al.
Neuro-Oncology|April 6, 2021
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomasYao Yu, Javier Villanueva-Meyer, Matthew R Grimmer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2026
A genomically-tailored multi-agent precision medicine clinical trial for adults with recurrent glioblastomaJiaying Chen, Nancy Ann Oberheim Bush, Jennifer A Grabowsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2023
Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 TrialDaphne A Haas-Kogan, Mariam S Aboian, Jane E Minturn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2020
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent GlioblastomaLakshmi Nayak, Annette M Molinaro, Katherine Peters, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2023
An expandable, modular de novo protein platform for precision redox engineeringGeorge H Hutchins, Claire E M Noble, H Adrian Bunzel, et al.
The Journal of Clinical Investigation|August 21, 2020
Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline gliomaSabine Mueller, Jared M Taitt, Javier E Villanueva-Meyer, et al.
Cancer Cell|September 17, 2015
DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain TumorsTali Mazor, Aleksandr Pankov, Brett E Johnson, et al.
Pageof 34

Showing results (291-300 of 336) with videos related to

Sort By:
Pageof 34
Neuro-Oncology|January 2, 2025
Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomideGeno Guerra, George Wendt, Lucie McCoy, et al.
Neuro-Oncology Advances|July 25, 2025
Dissecting the biology of gliomagenesis: Evaluating the interaction between <i>IDH</i> tumor mutation and germline variantsMatthew L Kosel, Paul A Decker, Thomas M Kollmeyer, et al.
Neuro-Oncology Advances|December 23, 2020
Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adultsJessica D Schulte, Robin A Buerki, Sarah Lapointe, et al.
Neuro-Oncology|April 6, 2021
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomasYao Yu, Javier Villanueva-Meyer, Matthew R Grimmer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2026
A genomically-tailored multi-agent precision medicine clinical trial for adults with recurrent glioblastomaJiaying Chen, Nancy Ann Oberheim Bush, Jennifer A Grabowsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2023
Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 TrialDaphne A Haas-Kogan, Mariam S Aboian, Jane E Minturn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2020
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent GlioblastomaLakshmi Nayak, Annette M Molinaro, Katherine Peters, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2023
An expandable, modular de novo protein platform for precision redox engineeringGeorge H Hutchins, Claire E M Noble, H Adrian Bunzel, et al.
The Journal of Clinical Investigation|August 21, 2020
Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline gliomaSabine Mueller, Jared M Taitt, Javier E Villanueva-Meyer, et al.
Cancer Cell|September 17, 2015
DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain TumorsTali Mazor, Aleksandr Pankov, Brett E Johnson, et al.
Pageof 34